| | Identification | Back Directory |  | [Name] 
 LMT-28
 |  | [CAS] 
 1239600-18-0
 |  | [Synonyms] 
 LMT-28
 LMT-28 >=98% (HPLC)
 2-Oxazolidinone, 3-[(2S,3S)-3-hydroxy-2-methyl-4-methylene-1-oxononyl]-4-(1-methylethyl)-, (4S)-
 |  | [Molecular Formula] 
 C17H29NO4
 |  | [MDL Number] 
 MFCD30187587
 |  | [MOL File] 
 1239600-18-0.mol
 |  | [Molecular Weight] 
 311.42
 | 
 | Chemical Properties | Back Directory |  | [Boiling point ] 
 452.9±38.0 °C(Predicted)
 |  | [density ] 
 1.065±0.06 g/cm3(Predicted)
 |  | [storage temp. ] 
 -20°C
 |  | [solubility ] 
 100 mg/mL in DMSO (321.11 mM),
 |  | [form ] 
 oil
 |  | [pka] 
 13.97±0.20(Predicted)
 |  | [color ] 
 colorless to light yellow, oil
 |  | [Water Solubility ] 
 < 0.1 mg/mL Water (insoluble)
 | 
 | Hazard Information | Back Directory |  | [Uses] 
 LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130[1].
 |  | [Biochem/physiol Actions] 
 LMT-28 is a derivative of oxazolidinone. It has the ability to repress the activation of signal transducer and activator of transcription 3 (STAT3) stimulated by interleukin 6 (IL-6). Orally administered LMT-28 reduced arthritis and acute pancreatitis stimulated by collagen in mice pathologic models.
 |  | [in vivo] 
 
 LMT-28 (0-0.5 mg/kg; p.o.; once daily for 15 days) alleviates CIA in mice[1].LMT-28 (0.25 or 1 mg/kg; p.o.) ameliorates the progression of pancreatitis in mice. LMT-28 binds directly and specifically to gp130, and thereby inhibits the interaction of gp130 with the IL-6/IL-6Rα complex[1].
 | Animal Model: | Six-week-old male DBA/1J mice (collagen-induced arthritis mice, CIA)[1] |  | Dosage: | 0-0.5 mg/kg |  | Administration: | Oral; once daily for 15 days |  | Result: | Markedly reduced the serum levels of cartilage oligomeric matrix protein (COMP) by 50%, serum amyloid P (SAP) by 55%, and anti-CII IgG by 62%. | 
 |  | [IC 50] 
 IL-6
 |  | [References] 
 [1] Hong SS, et al. A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor β Subunit, Glycoprotein 130. J Immunol. 2015 Jul 1;195(1):237-45. DOI:10.4049/jimmunol.1402908
 | 
 | 
                    
                        
                            | Company Name: | Sigma-Aldrich |  
                            | Tel: | 021-61415566 800-8193336 |  
                            | Website: | https://www.sigmaaldrich.cn |  
                    
                        
                            | Company Name: | Energy Chemical |  
                            | Tel: | 021-58432009 400-005-6266 |  
                            | Website: | http://www.energy-chemical.com |  |